Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer India Launches Two Drugs With Hemas In Sri Lanka

This article was originally published in PharmAsia News

Executive Summary

Pfizer's India arm is launching a pair of drugs in Sri Lanka, one for treating cancer, the other inflammatory disorders, using Hemas Pharmaceuticals as prime distributor. Pfizer India's Managing Director Kewal Handa said the launch is part of the firm's plans to increase its Sri Lanka business, with several more key therapeutic drugs to be launched over the next three years. The two drugs leading the way are Pfizer India's Sutent (sunitinib) for life-threatening cancers and Medrol (methylprednisolone) for use when inflammatory disorders do not respond to conventional drugs satisfactorily. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts